Literature DB >> 23348740

67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosis.

Motofumi Kumazoe1, Kaori Sugihara, Shuntaro Tsukamoto, Yuhui Huang, Yukari Tsurudome, Takashi Suzuki, Yumi Suemasu, Naoki Ueda, Shuya Yamashita, Yoonhee Kim, Koji Yamada, Hirofumi Tachibana.   

Abstract

The 67-kDa laminin receptor (67LR) is a laminin-binding protein overexpressed in various types of cancer, including bile duct carcinoma, colorectal carcinoma, cervical cancer, and breast carcinoma. 67LR plays a vital role in growth and metastasis of tumor cells and resistance to chemotherapy. Here, we show that 67LR functions as a cancer-specific death receptor. In this cell death receptor pathway, cGMP initiated cancer-specific cell death by activating the PKCδ/acid sphingomyelinase (PKCδ/ASM) pathway. Furthermore, upregulation of cGMP was a rate-determining process of 67LR-dependent cell death induced by the green tea polyphenol (-)-epigallocatechin-3-O-gallate (EGCG), a natural ligand of 67LR. We found that phosphodiesterase 5 (PDE5), a negative regulator of cGMP, was abnormally expressed in multiple cancers and attenuated 67LR-mediated cell death. Vardenafil, a PDE5 inhibitor that is used to treat erectile dysfunction, significantly potentiated the EGCG-activated 67LR-dependent apoptosis without affecting normal cells and prolonged the survival time in a mouse xenograft model. These results suggest that PDE5 inhibitors could be used to elevate cGMP levels to induce 67LR-mediated, cancer-specific cell death.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23348740      PMCID: PMC3561824          DOI: 10.1172/JCI64768

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  44 in total

1.  Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice.

Authors:  Joshua D Lambert; Mary J Kennett; Shengmin Sang; Kenneth R Reuhl; Jihyeung Ju; Chung S Yang
Journal:  Food Chem Toxicol       Date:  2009-10-31       Impact factor: 6.023

2.  Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications.

Authors:  Masood A Shammas; Paola Neri; Hemanta Koley; Ramesh B Batchu; Robert C Bertheau; Vidit Munshi; Rao Prabhala; Mariateresa Fulciniti; Yu Tzu Tai; Steven P Treon; Raj K Goyal; Kenneth C Anderson; Nikhil C Munshi
Journal:  Blood       Date:  2006-06-29       Impact factor: 22.113

Review 3.  Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.

Authors:  M M Goldenberg
Journal:  Clin Ther       Date:  1999-02       Impact factor: 3.393

4.  Direct inhibition of insulin-like growth factor-I receptor kinase activity by (-)-epigallocatechin-3-gallate regulates cell transformation.

Authors:  Ming Li; Zhiwei He; Svetlana Ermakova; Duo Zheng; Faqing Tang; Yong-Yeon Cho; Feng Zhu; Wei-Ya Ma; Yuk Sham; Evgeny A Rogozin; Ann M Bode; Ya Cao; Zigang Dong
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2007-03       Impact factor: 4.254

5.  The 67-kDa laminin-binding protein is involved in shear stress-dependent endothelial nitric-oxide synthase expression.

Authors:  T Gloe; S Riedmayr; H Y Sohn; U Pohl
Journal:  J Biol Chem       Date:  1999-06-04       Impact factor: 5.157

6.  Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study.

Authors:  Saverio Bettuzzi; Maurizio Brausi; Federica Rizzi; Giovanni Castagnetti; Giancarlo Peracchia; Arnaldo Corti
Journal:  Cancer Res       Date:  2006-01-15       Impact factor: 12.701

7.  Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways.

Authors:  Siyuan Zhang; Wen-Chien Huang; Ping Li; Hua Guo; Say-Bee Poh; Samuel W Brady; Yan Xiong; Ling-Ming Tseng; Shau-Hsuan Li; Zhaoxi Ding; Aysegul A Sahin; Francisco J Esteva; Gabriel N Hortobagyi; Dihua Yu
Journal:  Nat Med       Date:  2011-03-13       Impact factor: 53.440

8.  Hypoxia-mediated up-regulation of MGr1-Ag/37LRP in gastric cancers occurs via hypoxia-inducible-factor 1-dependent mechanism and contributes to drug resistance.

Authors:  Lili Liu; Li Sun; Hongbo Zhang; Zhichao Li; Xiaoxuan Ning; Yongquan Shi; Changcun Guo; Shuang Han; Kaichun Wu; Daiming Fan
Journal:  Int J Cancer       Date:  2009-04-01       Impact factor: 7.396

9.  The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells.

Authors:  Seiji Adachi; Tomokazu Nagao; Helgi I Ingolfsson; Frederick R Maxfield; Olaf S Andersen; Levy Kopelovich; I Bernard Weinstein
Journal:  Cancer Res       Date:  2007-07-01       Impact factor: 12.701

10.  Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma.

Authors:  Bojie Dai; X Frank Zhao; Krystyna Mazan-Mamczarz; Patrick Hagner; Sharon Corl; El Mustapha Bahassi; Song Lu; Peter J Stambrook; Paul Shapiro; Ronald B Gartenhaus
Journal:  Nat Commun       Date:  2011-07-19       Impact factor: 14.919

View more
  62 in total

Review 1.  Tea and human health: biomedical functions of tea active components and current issues.

Authors:  Zong-mao Chen; Zhi Lin
Journal:  J Zhejiang Univ Sci B       Date:  2015-02       Impact factor: 3.066

2.  Green Tea Polyphenol Epigallocatechin-3-gallate Suppresses Toll-like Receptor 4 Expression via Up-regulation of E3 Ubiquitin-protein Ligase RNF216.

Authors:  Motofumi Kumazoe; Yuki Nakamura; Mai Yamashita; Takashi Suzuki; Kanako Takamatsu; Yuhui Huang; Jaehoon Bae; Shuya Yamashita; Motoki Murata; Shuhei Yamada; Yuki Shinoda; Wataru Yamaguchi; Yui Toyoda; Hirofumi Tachibana
Journal:  J Biol Chem       Date:  2017-02-01       Impact factor: 5.157

3.  Phosphodiesterase sequence variants may predispose to prostate cancer.

Authors:  Rodrigo B de Alexandre; Anelia D Horvath; Eva Szarek; Allison D Manning; Leticia F Leal; Fabio Kardauke; Jonathan A Epstein; Dirce M Carraro; Fernando A Soares; Tatiyana V Apanasovich; Constantine A Stratakis; Fabio R Faucz
Journal:  Endocr Relat Cancer       Date:  2015-05-15       Impact factor: 5.678

4.  Effects of Tea Catechins on Cancer Signaling Pathways.

Authors:  Chung S Yang; Hong Wang; Jayson X Chen; Jinsong Zhang
Journal:  Enzymes       Date:  2014

5.  FOXO3 is essential for CD44 expression in pancreatic cancer cells.

Authors:  M Kumazoe; M Takai; J Bae; S Hiroi; Y Huang; K Takamatsu; Y Won; M Yamashita; S Hidaka; S Yamashita; S Yamada; M Murata; S Tsukamoto; H Tachibana
Journal:  Oncogene       Date:  2016-11-28       Impact factor: 9.867

6.  Inhibition of retinal neovascularization by a PEDF-derived nonapeptide in newborn mice subjected to oxygen-induced ischemic retinopathy.

Authors:  Nader Sheibani; Ismail S Zaitoun; Shoujian Wang; Soesiawati R Darjatmoko; Andrew Suscha; Yong-Seok Song; Christine M Sorenson; Victor Shifrin; Daniel M Albert; Ignacio Melgar-Asensio; Irawati Kandela; Jack Henkin
Journal:  Exp Eye Res       Date:  2020-04-06       Impact factor: 3.467

Review 7.  cGMP: transition from bench to bedside: a report of the 6th International Conference on cGMP Generators, Effectors and Therapeutic Implications.

Authors:  Linda S Hoffmann; Horng H Chen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-06-15       Impact factor: 3.000

8.  Alterations in the cerebellar (Phospho)proteome of a cyclic guanosine monophosphate (cGMP)-dependent protein kinase knockout mouse.

Authors:  Eleonora Corradini; Raghavan Vallur; Linsey M Raaijmakers; Susanne Feil; Robert Feil; Albert J R Heck; Arjen Scholten
Journal:  Mol Cell Proteomics       Date:  2014-06-12       Impact factor: 5.911

Review 9.  Lessons learned from cancer prevention studies with nutrients and non-nutritive dietary constituents.

Authors:  Chung S Yang; Jayson X Chen; Hong Wang; Justin Lim
Journal:  Mol Nutr Food Res       Date:  2016-05-09       Impact factor: 5.914

10.  Cancer therapy combination: green tea and a phosphodiesterase 5 inhibitor?

Authors:  Chung S Yang; Hong Wang
Journal:  J Clin Invest       Date:  2013-01-25       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.